disease may be the most homogeneous category, because it represents intrinsic atherosclerotic disease in the extracranial or intracranial arteries.
In the study reported in this issue, Nybo and coworkers used a careful case-control design within a large prospectively collected cohort from Scandinavia (3 ) . Blood drawn at baseline was used to measure osteoprotegerin concentrations to predict future stroke. Cases of stroke were identified by using administrative data coding of stroke. The definition chosen was liberal and probably highly sensitive to patients admitted to a hospital with stroke of any type (8 ) . However, many patients with transient ischemic attack or minor stroke either may not seek medical attention or they may be seen in a clinic or emergency ward and never be admitted to the hospital. Without an admission these patients will not ever be coded as a "stroke discharge." Thus the possibility of misclassification bias, although small, remains.
The authors carefully classified ischemic stroke subtype according to the TOAST criteria. They performed this classification retrospectively by chart review. Without knowing the extent of the investigations completed, it is difficult to be certain that the classification is accurate. However, the quality of stroke unit care in Denmark is generally excellent, and so we can conclude that it is likely that this approach was accurate enough. The distribution of stroke types is similar to that seen in other cohort studies and in randomized trials of ischemic stroke patients. However, the TOAST categories illustrate that we are dealing with multiple underlying disease processes that cause ischemic stroke. Therefore, it may not be surprising that no relationship emerges with a single biomarker. Given the postulated biological mechanism for the inhibitory role of osteoprotegerin in vascular calcification, it would be of great interest to see if a relationship between ischemic stroke due to large artery disease and osteoprotegerin could be found.
Given that stroke is an episodic manifestation of its underlying cause or causes, why should we assume that a single measurement taken at one point in time would predict future stroke events? Perhaps, when the underlying cause (e.g., atrial fibrillation) is quiescent, the biomarker is quiescent. The timing of the protein measurement may be very relevant.
In summary, the search for biomarkers for stroke must go on, but it must be done according to specific stroke types. As our understanding of stroke progresses, we must also adjust our study methods. De-tailed understanding of stroke mechanisms (in both ischemia and hemorrhage) is necessary to the identification of clinically relevant correlations of stroke with protein biomarkers and genetic characteristics. Lumping all types of stroke together is no longer a fruitful approach to such investigations.
